These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 24290142)

  • 41. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y; Duan Q; Wang S; Zeng Y; Wu R
    J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
    Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
    J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. F-18 fluorodeoxyglucose uptake in a solid pseudopapillary tumor of the pancreas mimicking malignancy.
    Shimada K; Nakamoto Y; Isoda H; Maetani Y; Yamashita R; Arizono S; Hirokawa Y; Nitta T; Doi R; Haga H; Togashi K
    Clin Nucl Med; 2008 Nov; 33(11):766-8. PubMed ID: 18936608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
    Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
    AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.
    Hyun SH; Kim HS; Choi SH; Choi DW; Lee JK; Lee KH; Park JO; Lee KH; Kim BT; Choi JY
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1461-8. PubMed ID: 26872788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
    Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
    PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
    Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
    Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors.
    Luo G; Liu Z; Guo M; Jin K; Xiao Z; Liu L; Xu J; Zhang B; Liu C; Huang D; Hu S; Ni Q; Long J; Yu X
    Int J Oncol; 2014 Oct; 45(4):1531-6. PubMed ID: 25096059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis.
    Hu S; Zhang J; Cheng C; Liu Q; Sun G; Zuo C
    Abdom Imaging; 2014 Dec; 39(6):1221-7. PubMed ID: 24913670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
    Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
    J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
    Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
    Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
    Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
    J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.
    Xu HX; Chen T; Wang WQ; Wu CT; Liu C; Long J; Xu J; Zhang YJ; Chen RH; Liu L; Yu XJ
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1093-102. PubMed ID: 24522797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.
    Foley KG; Fielding P; Lewis WG; Karran A; Chan D; Blake P; Roberts SA
    Eur J Radiol; 2014 Jul; 83(7):1069-1073. PubMed ID: 24794862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction.
    Sheikhbahaei S; Wray R; Young B; Mena E; Taghipour M; Rahmim A; Subramaniam RM
    Nucl Med Commun; 2016 Mar; 37(3):231-8. PubMed ID: 26575392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
    Caglar M; Yener C; Karabulut E
    Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.